HOME >> BIOLOGY >> NEWS
FDA approves AVELOX (moxifloxacin HCl) for treatment of complicated intra-abdominal infections

Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved the once-daily, broad-spectrum antibiotic AVELOX (moxifloxacin HCl) for a new use the treatment of complicated intra-abdominal infections (cIAI) in adults. AVELOX is the only marketed fluoroquinolone antibiotic approved by the FDA as monotherapy to treat this indication. The FDA approval to treat cIAI is the sixth indication for AVELOX.

AVELOX, available in tablet and intravenous (I.V.) formulations, was developed by Bayer Pharmaceuticals Corporation and is marketed in the United States by Schering-Plough.

Intra-abdominal infections are caused by disease, trauma or surgery in the abdomen that cause bacteria to leak from the gastrointestinal tract into adjacent tissue there are approximately 3.5 million cases in the United States each year, with many patients contracting the infection secondary to appendicitis. [1]

"The FDA approval of AVELOX to treat complicated intra-abdominal infections is welcome news, providing doctors with an effective treatment option for their patients, and giving patients convenient once-daily dosing and an easy transition from I.V. to oral therapy when they leave the hospital," said Joseph S. Solomkin, M.D., professor in the department of surgery and director of research of the division of trauma/critical care at the University of Cincinnati College of Medicine.

With this FDA approval, AVELOX is indicated for the treatment of adults with cIAI, including polymicrobial infections such as abscesses caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron or Peptostreptococcus species.

The FDA approval was based on results from clinical studies in cIAI patients showing that sequential I.V. or oral monotherapy with AVELOX once daily was
'"/>


30-Nov-2005


Page: 1 2

Related biology news :

1. FDA approves new epilepsy indication for Lamictal
2. US govt approves multi-million $ wild bird avian flu surveillance network
3. FDA approves extended dosing of Aranesp
4. FDA approves first medical device using Rutgers biomaterial
5. DFG approves additional six research training groups
6. FDA approves ABRAXANE(TM) for metastatic breast cancer
7. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
8. New system of wastewater treatment could reduce the size of treatment plants by half
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. Geisinger scientist seeks cure for Lou Gehrigs disease, creating device to find treatment
11. System to analyze beating heart stem cells could lead to heart attack treatments

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
Breaking Biology News(10 mins):
(Date:5/22/2017)... ... May 22, 2017 , ... Stratevi, a boutique firm that partners with ... It has opened an office in downtown Boston at 745 Atlantic Ave. , ... important to generate evidence on the value they provide, not just to patients, but ...
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose is ... trial and error process by finding the right antidepressant faster. CNSDose speeds ... doctor-patient relationship through a personalized approach to treatment. , A peer-reviewed ...
(Date:5/18/2017)... ... May 18, 2017 , ... Lajollacooks4u has added another option ... two-hour team-building package designed for groups of 10-30 people. Guests can choose ... items, such as Blackened Shrimp with Edamame Salad, Pizza Rolls with Pepperoni and ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... compliance and commercialization, has just released version 9.0 of the Cognition Cockpit platform. ... version of Cockpit,” says David Cronin, CEO of Cognition. “We’re thrilled to finally ...
Breaking Biology Technology:
Cached News: